Cargando…

Feasibility of [(68)Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma

BACKGROUND: [(68)Ga]Ga-FAPI-46 is a novel positron emission tomography (PET) ligand that targets fibroblast activation protein (FAP) expression as FAP inhibitor (FAPI) and could already show promising results in several tumor entities. It could be demonstrated that an increased FAP expression correl...

Descripción completa

Detalles Bibliográficos
Autores principales: Unterrainer, Lena M., Lindner, Simon, Eismann, Lennert, Casuscelli, Jozefina, Gildehaus, Franz-Josef, Bui, Vinh Ngoc, Albert, Nathalie L., Holzgreve, Adrien, Beyer, Leonie, Todica, Andrei, Brendel, Matthias, Cyran, Clemens C., Karl, Alexander, Stief, Christian G., Ledderose, Stephan T., Unterrainer, Marcus, Bartenstein, Peter, Wenter, Vera, Kretschmer, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308618/
https://www.ncbi.nlm.nih.gov/pubmed/35325283
http://dx.doi.org/10.1007/s00259-022-05761-5
_version_ 1784753019978514432
author Unterrainer, Lena M.
Lindner, Simon
Eismann, Lennert
Casuscelli, Jozefina
Gildehaus, Franz-Josef
Bui, Vinh Ngoc
Albert, Nathalie L.
Holzgreve, Adrien
Beyer, Leonie
Todica, Andrei
Brendel, Matthias
Cyran, Clemens C.
Karl, Alexander
Stief, Christian G.
Ledderose, Stephan T.
Unterrainer, Marcus
Bartenstein, Peter
Wenter, Vera
Kretschmer, Alexander
author_facet Unterrainer, Lena M.
Lindner, Simon
Eismann, Lennert
Casuscelli, Jozefina
Gildehaus, Franz-Josef
Bui, Vinh Ngoc
Albert, Nathalie L.
Holzgreve, Adrien
Beyer, Leonie
Todica, Andrei
Brendel, Matthias
Cyran, Clemens C.
Karl, Alexander
Stief, Christian G.
Ledderose, Stephan T.
Unterrainer, Marcus
Bartenstein, Peter
Wenter, Vera
Kretschmer, Alexander
author_sort Unterrainer, Lena M.
collection PubMed
description BACKGROUND: [(68)Ga]Ga-FAPI-46 is a novel positron emission tomography (PET) ligand that targets fibroblast activation protein (FAP) expression as FAP inhibitor (FAPI) and could already show promising results in several tumor entities. It could be demonstrated that an increased FAP expression correlates with tumor aggressivity in urothelial carcinoma (UC). Given the limited value of [(18)F]FDG in UC, [(68)Ga]Ga-FAPI-46 could add diagnostic information in staging and response assessment in UC. We present the first data of [(68)Ga]Ga-FAPI-46 PET imaging in a pilot cohort of UC patients evaluating uptake characteristics in metastases and primary tumors. METHODS: Fifteen patients with UC prior to or after local treatment underwent [(68)Ga]Ga-FAPI-46 PET/CT imaging for detection of metastatic spread. We compared the biodistribution in non-affected organs and tumor uptake of UC lesions by standard uptake value measurements (SUV(mean) and SUV(max)). Additionally, metastatic sites on PET were compared to its morphological correlate on contrast-enhanced computed tomography (CT). RESULTS: Overall, 64 tumor sites were detected on PET and/or CT. The highest uptake intensity was noted at the primary site (SUV(max) 20.8 (range, 8.1–27.8)) followed by lymph node metastases (SUV(max) 10.6 (range, 4.7–29.1)). In 4/15 (26.7%) patients there were [(68)Ga]Ga-FAPI-46-positive lesions that were missed on standard routine CT imaging. On the other hand, 2/15 patients had suspicious prominent bipulmonary nodules as well as pelvic lymph nodes previously rated as suspicious for metastatic spread on CT, but without increased FAPI expression; here histopathology excluded malignancy. CONCLUSION: [(68)Ga]Ga-FAPI-46 PET shows distinctly elevated uptake in UC lesions. Therefore, the tracer has potential as a promising new biomarker in metastatic UC patients, as [(68)Ga]Ga-FAPI-46 PET might improve detection of metastatic sites compared to CT alone. These findings highly emphasize larger studies investigating FAPI imaging in UC patients.
format Online
Article
Text
id pubmed-9308618
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-93086182022-07-25 Feasibility of [(68)Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma Unterrainer, Lena M. Lindner, Simon Eismann, Lennert Casuscelli, Jozefina Gildehaus, Franz-Josef Bui, Vinh Ngoc Albert, Nathalie L. Holzgreve, Adrien Beyer, Leonie Todica, Andrei Brendel, Matthias Cyran, Clemens C. Karl, Alexander Stief, Christian G. Ledderose, Stephan T. Unterrainer, Marcus Bartenstein, Peter Wenter, Vera Kretschmer, Alexander Eur J Nucl Med Mol Imaging Original Article BACKGROUND: [(68)Ga]Ga-FAPI-46 is a novel positron emission tomography (PET) ligand that targets fibroblast activation protein (FAP) expression as FAP inhibitor (FAPI) and could already show promising results in several tumor entities. It could be demonstrated that an increased FAP expression correlates with tumor aggressivity in urothelial carcinoma (UC). Given the limited value of [(18)F]FDG in UC, [(68)Ga]Ga-FAPI-46 could add diagnostic information in staging and response assessment in UC. We present the first data of [(68)Ga]Ga-FAPI-46 PET imaging in a pilot cohort of UC patients evaluating uptake characteristics in metastases and primary tumors. METHODS: Fifteen patients with UC prior to or after local treatment underwent [(68)Ga]Ga-FAPI-46 PET/CT imaging for detection of metastatic spread. We compared the biodistribution in non-affected organs and tumor uptake of UC lesions by standard uptake value measurements (SUV(mean) and SUV(max)). Additionally, metastatic sites on PET were compared to its morphological correlate on contrast-enhanced computed tomography (CT). RESULTS: Overall, 64 tumor sites were detected on PET and/or CT. The highest uptake intensity was noted at the primary site (SUV(max) 20.8 (range, 8.1–27.8)) followed by lymph node metastases (SUV(max) 10.6 (range, 4.7–29.1)). In 4/15 (26.7%) patients there were [(68)Ga]Ga-FAPI-46-positive lesions that were missed on standard routine CT imaging. On the other hand, 2/15 patients had suspicious prominent bipulmonary nodules as well as pelvic lymph nodes previously rated as suspicious for metastatic spread on CT, but without increased FAPI expression; here histopathology excluded malignancy. CONCLUSION: [(68)Ga]Ga-FAPI-46 PET shows distinctly elevated uptake in UC lesions. Therefore, the tracer has potential as a promising new biomarker in metastatic UC patients, as [(68)Ga]Ga-FAPI-46 PET might improve detection of metastatic sites compared to CT alone. These findings highly emphasize larger studies investigating FAPI imaging in UC patients. Springer Berlin Heidelberg 2022-03-24 2022 /pmc/articles/PMC9308618/ /pubmed/35325283 http://dx.doi.org/10.1007/s00259-022-05761-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Unterrainer, Lena M.
Lindner, Simon
Eismann, Lennert
Casuscelli, Jozefina
Gildehaus, Franz-Josef
Bui, Vinh Ngoc
Albert, Nathalie L.
Holzgreve, Adrien
Beyer, Leonie
Todica, Andrei
Brendel, Matthias
Cyran, Clemens C.
Karl, Alexander
Stief, Christian G.
Ledderose, Stephan T.
Unterrainer, Marcus
Bartenstein, Peter
Wenter, Vera
Kretschmer, Alexander
Feasibility of [(68)Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma
title Feasibility of [(68)Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma
title_full Feasibility of [(68)Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma
title_fullStr Feasibility of [(68)Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma
title_full_unstemmed Feasibility of [(68)Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma
title_short Feasibility of [(68)Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma
title_sort feasibility of [(68)ga]ga-fapi-46 pet/ct for detection of nodal and hematogenous spread in high-grade urothelial carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308618/
https://www.ncbi.nlm.nih.gov/pubmed/35325283
http://dx.doi.org/10.1007/s00259-022-05761-5
work_keys_str_mv AT unterrainerlenam feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT lindnersimon feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT eismannlennert feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT casuscellijozefina feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT gildehausfranzjosef feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT buivinhngoc feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT albertnathaliel feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT holzgreveadrien feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT beyerleonie feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT todicaandrei feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT brendelmatthias feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT cyranclemensc feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT karlalexander feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT stiefchristiang feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT ledderosestephant feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT unterrainermarcus feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT bartensteinpeter feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT wentervera feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma
AT kretschmeralexander feasibilityof68gagafapi46petctfordetectionofnodalandhematogenousspreadinhighgradeurothelialcarcinoma